Listen
Reason for request
Inclusion
Substantial clinical benefit but no demonstrated clinical added value in the treatment of chronic cancer pain not adequately relieved by other step 3 opioids
- ZORYON has an MA in the chronic treatment of moderate to severe cancer pain in patients not adequately relieved by other step 3 opioids.
- Methadone has been used off-label for numerous years in the treatment of patients with chronic cancer pain. Treatment with ZORYON (methadone) may be initiated in these patients during a step 3 opioid rotation.
- The pharmacokinetic characteristics and safety data for methadone call for caution when initiating treatment; initiation should be performed in a hospital setting by a pain management or palliative care team experienced in the use of the product.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Documents
English version
Contact Us
Évaluation des médicaments
